Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 1/20 | 0.48 |
| ▸ | JAK1 | P23458 | 1/20 | 0.48 |
| ▸ | TYK2 | P29597 | 1/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | HCRTR1 | O43613 | 15/20 | 0.43 |
| ▸ | HCRTR2 | O43614 | 15/20 | 0.43 |
| ▸ | KDM5A | P29375 | 1/20 | 0.43 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.41 |
| ▸ | ATR | Q13535 | 1/20 | 0.37 |
| ▸ | BTK | Q06187 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5769639 | 0.88 | ATR (0.43) | JAK2JAK1TYK2JAK3HCRTR1 | |
| SCHEMBL5811219 | 0.88 | ATR (0.40) | JAK2JAK1TYK2JAK3HCRTR1 | |
| SCHEMBL5768174 | 0.87 | KDM5A (0.39) | JAK2JAK1TYK2JAK3KDM5A | |
| SCHEMBL5772822 | 0.87 | KDM5A (0.39) | JAK2JAK1TYK2JAK3KDM5A | |
| SCHEMBL5771644 | 0.85 | ATR (0.42) | JAK2HCRTR1HCRTR2KDM5AMCHR1 | |
| SCHEMBL5773738 | 0.85 | ATR (0.42) | JAK2HCRTR1HCRTR2KDM5AMCHR1 | |
| SCHEMBL5773750 | 0.84 | ATR (0.41) | JAK2JAK1TYK2JAK3MCHR1 | |
| SCHEMBL5774263 | 0.83 | ATR (0.40) | HCRTR1HCRTR2MCHR1ATR | |
| SCHEMBL5873060 | 0.82 | DYRK1A (0.40) | HCRTR1HCRTR2KDM5AATR | |
| SCHEMBL5873091 | 0.80 | KDM5A (0.41) | KDM5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1664040-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2006-06-07 | — | — | EP | disclosed |
| US-6984652-B2 | Gyrase inhibitors | WARNER-LAMBERT COMPANY LLC (US) | 2006-01-10 | — | — | US | disclosed |
| US-20050250823-A1 | Gyrase inhibitors | YAGER KRAIG | 2005-11-10 | — | — | US | disclosed |
| WO-2005026162-A1 | GYRASE INHIBITORS | PFIZER INC. (US) | 2005-03-24 | — | — | WO | disclosed |
| US-20050054697-A1 | Gyrase inhibitors | PFIZER INC. | 2005-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050054697-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | JAK2 4304/4885JAK1 4092/4885TYK2 1897/4885 |
| US-20050250823-A1 | Gyrase inhibitors | TOP1, TOP2A, TOP2B | JAK2 4304/4885JAK1 4092/4885TYK2 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.